Taken together, these results demonstrate that immunomodulation with SA-4-1BBL is effective in preventing the conversion of conventional CD4+ T cells into CD4+CD25+FoxP3+ T cells in a tumor microenvironment. The gene discussed is CD4; the disease is neoplasm.